As of 2026, families and clinicians finally have a real choice for treating agitation in Alzheimer’s disease: two medications now hold full FDA approval for this specific condition. Rexulti (brexpiprazole), an atypical antipsychotic, became the first approved treatment in May 2023. Auvelity (dextromethorphan-bupropion) joined it on April 30, 2026, when the FDA approved it as the first non-antipsychotic drug for agitation associated with dementia due to Alzheimer’s disease. These are completed approvals, not pending applications — both drugs can be prescribed for this indication today. The distinction between the two matters enormously in practice.
Consider a typical scenario: an 82-year-old woman with moderate Alzheimer’s who paces, shouts, and occasionally strikes out at caregivers during evening hours. Before 2023, her physician would have faced an uncomfortable choice between off-label antipsychotics carrying a boxed warning about increased death rates in elderly dementia patients, or non-drug approaches that often fall short for severe symptoms. Now that physician can weigh Rexulti’s longer track record against Auvelity’s different mechanism and different safety profile — a genuine clinical decision rather than a workaround. Neither drug is a cure for agitation, and both come with meaningful caveats, including debates about how large their benefits really are. What follows is a detailed comparison of how each was approved, what the trials actually showed, and what families should ask about before starting either one.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the FDA's April 2026 approval announcement for Auvelity in Alzheimer's agitation — Readers can verify the approval details, trial results, and safety information for the first non-antipsychotic treatment directly from the FDA.
- Review the FDA's 2023 approval announcement for Rexulti (brexpiprazole) — Readers can confirm Rexulti's approval basis, dosing studies, and boxed-warning safety considerations from the regulator's own notice.
Table of Contents
- What Are the FDA-Approved Treatments for Alzheimer’s Agitation, and How Do Auvelity and Rexulti Differ?
- What the Clinical Trials Actually Showed — and Where the Evidence Is Mixed
- The Controversy Over Rexulti’s Effect Size
- Dosing, Practical Use, and the Tradeoffs Between the Two Drugs
- Side Effects and Safety Warnings Families Should Understand
- How Doctors Decide Between Auvelity and Rexulti
- Why the “First Non-Antipsychotic” Label Matters
- Frequently Asked Questions
What Are the FDA-Approved Treatments for Alzheimer’s Agitation, and How Do Auvelity and Rexulti Differ?
Rexulti (brexpiprazole) was approved for agitation associated with dementia due to Alzheimer’s disease in May 2023, following a supplemental new drug application from Otsuka and Lundbeck. It was the first drug ever approved by the fda for this condition, and the Alzheimer’s Association issued a statement marking the milestone. Rexulti is an atypical antipsychotic taken as an oral tablet, and it had already been on the market for schizophrenia and as an adjunct for major depression before gaining the agitation indication. auvelity took a fundamentally different path. Approved for Alzheimer’s agitation on April 30, 2026, it is an extended-release oral tablet combining dextromethorphan — an NMDA receptor antagonist and sigma-1 receptor agonist — with bupropion, which serves mainly to raise dextromethorphan levels in the blood.
Axsome Therapeutics originally won approval for Auvelity in major depressive disorder in 2022. For the agitation indication, the FDA granted it both breakthrough therapy and priority review designations, and its approval made it the first non-antipsychotic option for this condition. The practical comparison comes down to drug class. Antipsychotics as a group carry a boxed warning about increased mortality when used in elderly patients with dementia-related psychosis — a warning that has made many geriatricians reluctant to prescribe them long-term. Auvelity, not being an antipsychotic, does not carry that particular warning, though it has its own safety considerations discussed below. For a family weighing options, that single difference often frames the entire conversation.
What the Clinical Trials Actually Showed — and Where the Evidence Is Mixed
Auvelity’s approval rested on two key studies. In ADVANCE-1, a Phase 2/3 trial, patients on Auvelity saw their scores on the Cohen-Mansfield Agitation Inventory (CMAI) — the standard scale for measuring dementia agitation — fall by an average of 15.4 points at week 5, compared with 11.5 points for placebo, a statistically significant difference (p=0.010). The second pivotal study, ACCORD-2, tested something different: whether the drug keeps agitation from coming back. Among patients who initially responded and then continued Auvelity, only 8.4% relapsed over up to six months, versus 28.6% of those switched to placebo — roughly a 72% relative reduction in relapse risk. Axsome states Auvelity is the only approved product to demonstrate a statistically longer time to agitation relapse versus placebo in a long-term study. But the evidence is not uniformly positive, and a balanced reading requires acknowledging ADVANCE-2.
That 408-patient, five-week trial missed its primary endpoint: Auvelity produced a 13.8-point CMAI reduction against 12.6 points for placebo — a numerical edge only, not a statistically significant one. Anyone told that Auvelity “works” should also be told that one of its three major trials failed to separate from placebo in the short term. The high placebo responses in both ADVANCE trials also illustrate a broader truth in this field: agitation often improves with attention, structure, and time, regardless of medication. Rexulti’s approval was based on two Phase 3, 12-week, randomized, placebo-controlled fixed-dose trials, also using the CMAI. The pivotal study showed statistically significant improvement at 2–3 mg per day, with the sponsor reporting roughly 31% greater reduction in agitation symptoms versus placebo. The warning here is that “statistically significant” and “clinically meaningful” are not the same thing — a distinction explored in the next section.
The Controversy Over Rexulti’s Effect Size
Rexulti’s approval did not go unchallenged. The maximum difference between Rexulti and placebo on the CMAI was about 5.3 points on a scale that runs to 174 points. Some experts consider a difference of roughly 17 points the threshold for a clinically meaningful change — meaning Rexulti’s measured benefit fell well below what those critics regard as noticeable at the bedside. Published criticism followed the approval, including coverage from the BMJ Group questioning the fast-tracking of an antipsychotic for dementia agitation, and commentary in psychiatric trade publications describing the approval as controversial. A concrete way to picture this: the CMAI tallies the frequency of behaviors like pacing, cursing, grabbing, and hitting.
A 5-point improvement spread across dozens of items might mean an episode or two fewer per week — potentially real, but easy for a caregiver to miss amid the daily variability of dementia behavior. Defenders of the approval counter that in a condition with no previously approved treatment and enormous caregiver burden, even modest average benefits can matter, and that averages conceal individual patients who respond strongly. This controversy is worth keeping in mind when comparing marketing claims for either drug. Auvelity’s successful trial showed a roughly 3.9-point advantage over placebo at week 5 in ADVANCE-1 (15.4 versus 11.5) — a margin in the same modest territory as Rexulti’s. Neither drug transforms agitation; at best, each shifts it meaningfully for some patients.
Dosing, Practical Use, and the Tradeoffs Between the Two Drugs
Auvelity’s dosing for Alzheimer’s agitation starts at one 30 mg/105 mg tablet once daily in the morning. On day 8, the dose can be increased to the maximum of 45 mg/105 mg once daily based on tolerability. The morning dosing and simple one-step titration are practical advantages in dementia care, where complicated regimens burden caregivers and increase errors. Rexulti is also a once-daily oral tablet, titrated over roughly two weeks to the effective 2–3 mg range used in its trials. The central tradeoff is between track record and drug class.
Rexulti has been used for Alzheimer’s agitation since 2023 and for other psychiatric conditions since 2015, giving clinicians years of real-world familiarity — but it is an antipsychotic, with the class-wide boxed warning about elevated mortality in elderly dementia patients hanging over long-term use. Auvelity avoids the antipsychotic class entirely and brings relapse-prevention data from ACCORD-2 that Rexulti lacks, but it is newer to this population, and one of its short-term trials missed its endpoint. Cost and coverage add another layer. Both are brand-name drugs without generic equivalents for these formulations, and insurance plans may require trying non-drug approaches or other medications first. Families should ask the prescriber and pharmacy about prior authorization requirements before assuming either drug will be covered, since delays of weeks are common with newly approved indications.
Side Effects and Safety Warnings Families Should Understand
Auvelity’s freedom from the antipsychotic mortality warning does not make it warning-free. It carries the boxed warning common to antidepressants regarding suicidal thoughts and behaviors in adolescents and young adults, plus warnings for seizures, hypertension, and activation of mania. The seizure risk stems largely from the bupropion component and matters in elderly patients with a history of seizures or conditions that lower the seizure threshold. Blood pressure should be monitored, particularly in a population where hypertension is already common. On the encouraging side, in ADVANCE-1 and ACCORD-2 Auvelity was not associated with sedation or cognitive decline — two of the most feared effects of behavioral medications in dementia, since a drug that quiets agitation by dulling the patient trades one harm for another. Rexulti carries the antipsychotic class boxed warning: elderly patients with dementia-related psychosis treated with antipsychotic drugs face an increased risk of death.
This is the single most important safety fact for families to understand before starting it. The warning does not mean Rexulti is forbidden in this population — the FDA approved it for exactly this use after weighing the data — but it does mean the decision should be deliberate, the dose kept as low as effective, and the need for continued treatment revisited regularly. A general warning applies to both drugs: neither should be the first response to new agitation. Sudden behavioral changes in a person with dementia frequently signal an untreated problem — a urinary tract infection, pain, constipation, a medication interaction, or an environmental stressor. Medicating agitation without ruling out these causes can mask a treatable condition. Guidelines consistently recommend identifying triggers and trying non-drug strategies first, reserving medication for symptoms that are severe, persistent, or dangerous.
How Doctors Decide Between Auvelity and Rexulti
In practice, the choice often follows the patient’s history and the family’s risk tolerance. A geriatric psychiatrist might lean toward Auvelity for a patient whose family is firmly opposed to antipsychotics, or for someone who responded well initially but relapsed after stopping a previous medication — the scenario ACCORD-2 directly tested, with its 8.4% versus 28.6% relapse split. Conversely, a clinician might choose Rexulti for a patient with a seizure history or uncontrolled hypertension, both of which weigh against Auvelity, or when a plan’s formulary makes Rexulti the accessible option.
Prior medication history matters too. Because Auvelity contains bupropion, it cannot be combined with other bupropion products (such as Wellbutrin) or used within 14 days of an MAOI, and dextromethorphan-containing cough medicines must be avoided while taking it. A careful medication reconciliation — including over-the-counter products — belongs in every conversation before starting either drug.
Why the “First Non-Antipsychotic” Label Matters
The FDA’s own announcement emphasized that Auvelity is the first non-antipsychotic drug approved for agitation associated with dementia due to Alzheimer’s disease, and the agency’s decision to grant breakthrough therapy and priority review designations signaled how seriously it viewed the unmet need. For years, surveys of nursing homes and memory-care units have documented widespread off-label antipsychotic use for dementia behaviors, prompting federal initiatives to reduce it. An approved non-antipsychotic gives facilities and prescribers a documented, on-label alternative for the first time.
The label distinction has concrete regulatory consequences as well. Nursing homes in the United States are measured and publicly reported on their antipsychotic prescribing rates, which creates institutional pressure to avoid drugs in that class. A resident switched from an off-label antipsychotic to Auvelity comes off that quality metric entirely, while a resident on Rexulti — despite its on-label status — remains an antipsychotic recipient in those counts. Families touring facilities can ask directly how the staff approaches agitation and which of the two approved medications, if either, their consulting physicians typically use.
Frequently Asked Questions
Is Auvelity FDA-approved for Alzheimer’s agitation?
Yes. The FDA approved Auvelity on April 30, 2026, for agitation associated with dementia due to Alzheimer’s disease, making it the first non-antipsychotic approved for this condition.
Which was approved first, Auvelity or Rexulti?
Rexulti was approved first, in May 2023, as the first-ever FDA-approved treatment for Alzheimer’s agitation. Auvelity followed in April 2026.
Does Auvelity carry the antipsychotic mortality warning?
No. Auvelity is not an antipsychotic and does not carry that boxed warning, but it does carry the antidepressant boxed warning about suicidal thoughts in adolescents and young adults, plus warnings for seizures, hypertension, and mania activation.
Did Auvelity work in all of its clinical trials?
No. ADVANCE-1 and ACCORD-2 met their primary endpoints, but ADVANCE-2 missed its primary endpoint, showing only a numerical improvement over placebo.
Why was Rexulti’s approval controversial?
Its maximum benefit over placebo was about 5.3 points on the 174-point CMAI scale, below the roughly 17-point threshold some experts consider clinically meaningful, prompting published criticism.
How is Auvelity dosed for agitation?
Treatment starts at 30 mg/105 mg once daily in the morning, increasing on day 8 to a maximum of 45 mg/105 mg once daily based on tolerability.
